This study explores the use of a cancer drug called Belantamab Mafodotin for patients with relapsed/refractory multiple myeloma (RRMM), a type of blood cancer. The study aims to test how well this drug, alone and with other cancer treatments, works in patients whose cancer has returned or hasn’t responded to previous treatments. Multiple myeloma affects plasma cells in bone marrow, and targeting a protein called BCMA on these cells can be effective.

• The study is open to patients over 18 with specific prior treatments and health conditions.
• Participants should expect several visits and tests to monitor health and cancer response.
• Risks include side effects from the drug, and certain medical conditions may exclude participation.

It's crucial to check eligibility criteria, as conditions like recent infections, certain allergies, or other health issues may prevent participation. Always discuss with your doctor to understand if joining is right for you.